论文部分内容阅读
为了解新生儿肺炎IL－2R的变化，采用ELISA法检测33例新生儿肺炎血清sIL－2R水平、PBMC体外PHA培养72小时mIL－2Rα表达及上清液sIL－2R水平，并与36例正常新生儿对照。结果：（1）患儿血清sIL－2R水平治疗前高于治疗后（P＜0.001），且治疗前后均高于对照（P＜001）；治疗前血清sIL－2R水平与病情轻重密切相关（P＜0．01）；（2）患儿mIL－2Rα表达治疗前后无显著性差异（P＞005），上清液SIL－2R水平治疗前低于治疗后（P＜0．05）；而治疗前后两者均低于对照（P＜0.05）。提示：血清sIL－2R水平可作为新生儿肺炎病情监视及疗效观察的参考指标；患儿PBMC在体内可能已被激活，在体外对PHA非特异刺激的敏感性降低。
In order to understand the changes of IL-2R in neonatal pneumonia, the levels of sIL-2R in 33 cases of neonatal pneumonia, the expression of mIL-2Rα in 72 hours of PHA in vitro and the level of sIL-2R in supernatant were detected by ELISA. Neonatal control. Results: (1) Serum sIL-2R levels in children before treatment were significantly higher than those before treatment (P <0.001), and were significantly higher than those before treatment (P <001). Serum sIL-2R levels were closely related to the severity of illness P <0.01). (2) There was no significant difference in the expression of mIL-2Rα in children before and after treatment (P> 0.05), and the level of SIL-2R in the supernatant before treatment was lower than that before treatment Both before and after treatment were lower than the control (P <0.05). It is suggested that serum sIL-2R level can be used as a reference indicator for surveillance of neonatal pneumonia and observation of curative effect. PBMC in children may have been activated in vivo and the sensitivity to non-specific stimulation of PHA is reduced in vitro.